Sourcing Exosomes in Nevada
Licensed Nevada practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Nevada buyers need their own professional license and NPI; the wholesale license is the supplier’s obligation, not the purchaser’s.
Nevada deserves a closer read than most states. Its statute reaches biological products rather than only cells and tissues, which has led to a good deal of loose commentary about what is permitted here. The detail that matters is where that statute draws its boundaries. (Tennessee goes further still and names exosomes outright, which no other state does.)
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Nevada? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | AB 188 (2023) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 12 October 2026 |
Ordering from Nevada
ExaVeyra ships to licensed practices in all 50 states, Nevada included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Nevada professional license in good standing, verifiable through the Nevada State Board of Medical Examiners or the Nevada State Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Nevada resale certificate if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Nevada licenses wholesale distribution through the State Board of Pharmacy. NRS 639.233 reaches any person engaging in wholesale distribution, or furnishing controlled substances, poisons, drugs, devices, or appliances that federal law restricts to sale on a physician’s order, to anyone located in the state. A distributor counts as furnishing if it solicits or accepts orders, or receives, stores, or ships those items. Devices are inside the definition, as in California, New York, and Arizona. The license sits with the distributor, not with the purchasing practice.
NRS 639.233; NAC 639.702 to 639.7093 · Nevada State Board of Pharmacy
Nevada regenerative-medicine law
Nevada enacted AB 188, codified at NRS 630.3735 (physicians); NRS 633.6945 (osteopathic physicians), effective 1 July 2023.
Physicians licensed under chapter 630 and osteopathic physicians licensed under chapter 633. The statute sets consent-form and patient-information requirements, obliges the physician to notify the board of a patient death or hospitalization, requires the Board to report to the Legislature every two years, and provides that acting within its terms is not itself grounds for discipline. Manufacturers supplying under it maintain a round-the-clock hotline for patients who develop adverse effects and report quarterly to the medical boards. The 2023 amendments expire on 1 July 2027, when both sections revert to the 2015 right-to-try text, which covers only patients with a terminal condition, unless the Legislature acts first.
- Individualized investigational treatments produced for one patient
- Investigational products that have completed Phase 1 and are in an FDA-approved clinical trial
- Only for a diagnosed life-threatening or severely debilitating disease or condition
- Physician consent and reporting duties
- The 2023 amendments expire 1 July 2027, restoring the 2015 terminal-condition text
“a drug, biological product or device that is unique to and produced exclusively for use by an individual patient based on the genetic profile of the patient”
How this applies to exosomes
Nevada is often described as having legalized unapproved biologics, so it is worth being precise. Assembly Bill 188 does reach biological products, which is broader than the cells-and-tissues framing used in Florida, Texas, and California. Its gates are narrow, though. Every pathway requires a physician to have diagnosed a life-threatening or severely debilitating disease or condition and to have agreed with the patient that no FDA-approved treatment is adequate. Within that threshold, the statute reaches an individualized investigational treatment, which it defines as a drug, biological product, or device unique to and produced exclusively for one patient based on that patient’s genetic profile, and an investigational product that has completed Phase 1 and is being tested in an FDA-approved clinical trial. Topical aesthetic use is not a qualifying condition, and a Kimera preparation is allogeneic and made to a lot rather than to a patient’s genome, so the statute is not engaged. Exosome products remain governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Nevada practice
A designated medical director and a documented examination before treatment are the two things Nevada practices are most consistently expected to have in place. Because the availability standard for a delegating physician is set by board interpretation rather than by a single statutory sentence, it is worth confirming directly with the Board of Medical Examiners rather than relying on secondary summaries.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed under chapter 630, and osteopathic physicians under chapter 633, may perform medical acts within their scope and are the source of any delegation. Chapter 630 also treats practicing experimental medicine without patient consent as a ground for discipline, which is worth reading alongside the AB 188 consent requirements. |
| NP / APRN | Advanced practice registered nurses practice within the scope the Nevada State Board of Nursing establishes. Ownership of a practice delivering medical services is a separate question from clinical scope, and is governed by the corporate practice rules rather than by the Nurse Practice Act. |
| PA | Physician assistants practice under physician supervision within the delegated scope. |
| RN | Registered nurses may perform delegated treatments within their scope and under physician delegation. Nevada expects the delegating physician to remain readily available to the treatment site rather than merely on record, so confirm the current availability standard with the Board of Medical Examiners before setting protocols. |
Good faith examination
Nevada expects an examination establishing the practitioner-patient relationship before treatment is delivered, with a designated medical director available to the practice. Where a treatment falls under the AB 188 framework, the statute layers its own written consent form and patient information requirements on top of that.
Ownership and clinic licensing
Nevada recognizes the corporate practice of medicine doctrine and the State Board of Medical Examiners is an active enforcer of it, while management services arrangements between a non-physician entity and a clinical practice are widely used. The practical effect is a middle position: less codified than Texas or New York, but not the open field Arizona’s case-law-only posture suggests. Confirm your structure with Nevada counsel before opening.
Cold chain into Nevada
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Nevada order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Las Vegas | Clark | Largest Nevada market, with heavy aesthetic and concierge concentration. |
| Henderson | Clark | Affluent suburban market adjoining Las Vegas. |
| Reno | Washoe | Northern Nevada hub with a growing longevity segment. |
| Summerlin | Clark | Dense med spa corridor on the west side of the valley. |
| Sparks | Washoe | Served alongside Reno. |
| Carson City | State capital, smaller practice base. |
- Nevada orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
Wholesale exosome supply by city in Nevada
Each city page covers local receiving conditions, delivery disruptions and business license rules for Nevada practices in that area.
Practice types we supply in Nevada
Nevada licensing and verification
Nevada State Board of Medical Examiners
Physician license verification and the active enforcer of corporate practice limits.
Nevada State Board of Nursing
Nevada State Board of Pharmacy
Issues the wholesaler license held by out-of-state suppliers.
Nevada Department of Taxation
Where a practice registers before issuing a resale certificate.
Nevada sourcing questions
- Did Nevada legalize unapproved biologics?
- Not in the broad sense that phrase suggests. NRS 630.3735 and NRS 633.6945 are Nevada’s 2015 right-to-try sections. Assembly Bill 188 (2023) amended them so that a physician may also prescribe or recommend an individualized investigational treatment, defined as a drug, biological product, or device unique to and produced exclusively for one patient based on that patient’s genetic profile. Every pathway still requires a diagnosed life-threatening or severely debilitating disease or condition for which no FDA-approved treatment is adequate. The 2023 amendments expire on 1 July 2027, when both sections revert to the 2015 text, which covers only terminal conditions.
- Does AB 188 cover exosome products?
- It does not reach an off-the-shelf preparation. Every pathway requires a diagnosed life-threatening or severely debilitating disease or condition, and the statute’s individualized pathway turns on a product made exclusively for one patient from that patient’s genetic profile. A Kimera preparation is allogeneic and manufactured to a lot rather than to an individual genome, and topical aesthetic use is not a qualifying condition. Exosome products remain governed by federal law, and no exosome product is FDA-approved for administration to humans.
- Does my Nevada clinic need a wholesaler license to buy exosomes?
- No. The wholesaler license under NRS 639.233 is held by the distributor furnishing product into Nevada, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Does Nevada enforce the corporate practice of medicine?
- Yes, and the State Board of Medical Examiners is an active enforcer, while management services arrangements between a non-physician entity and a clinical practice are widely used. Nevada sits between the codified regimes in Texas and New York and Arizona’s case-law-only posture. Confirm your structure with Nevada counsel.
- What does Nevada expect before a treatment is delivered?
- An examination establishing the practitioner-patient relationship, a designated medical director available to the practice, and a delegating physician who remains readily available to the treatment site. Because the availability standard comes from board interpretation rather than a single statutory sentence, confirm it directly with the Board of Medical Examiners.
- How long does cold-chain shipping take to Nevada?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 12 October 2026 by Benn Bluestein-Veyra, M.Sc. Organic Chemistry. Every claim above links to a primary source.
- NRS ch. 630, Physicians (incl. § 630.3735, individualized investigational treatment) (accessed 8 August 2026)
- NRS ch. 639, Pharmacists and Pharmacy (incl. § 639.233) (accessed 8 August 2026)
- NAC ch. 639, wholesaler rules (accessed 8 August 2026)
- NRS ch. 454, § 454.690 (definitions, manufacturer hotline and reporting) (accessed 12 October 2026)
- Nevada Legislature, Assembly Bill 188 (2023), first reprint (effective 1 July 2023; amendments expire 1 July 2027) (accessed 12 October 2026)
- Nevada State Board of Medical Examiners (accessed 8 August 2026)
- Nevada State Board of Pharmacy (accessed 8 August 2026)
- Nevada Department of Taxation (accessed 8 August 2026)
- FDA Public Safety Notification on Exosome Products (accessed 8 August 2026)
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.